Valbiotis Beheer

Beheer criteriumcontroles 4/4

De CEO Valbiotis is Sebastien Peltier, benoemd in Mar2017, heeft een ambtstermijn van 7.67 jaar. De totale jaarlijkse vergoeding van { bedraagt € 301.00K, bestaande uit 59.8% salaris en 40.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 4% van de aandelen van het bedrijf, ter waarde € 769.74K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.8 jaar en 7.1 jaar.

Belangrijke informatie

Sebastien Peltier

Algemeen directeur

€301.0k

Totale compensatie

Percentage CEO-salaris	59.8%
Dienstverband CEO	7.7yrs
Eigendom CEO	4.0%
Management gemiddelde ambtstermijn	5.8yrs
Gemiddelde ambtstermijn bestuur	7.1yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Sebastien Peltier's beloning veranderd ten opzichte van Valbiotis's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-€9m
Mar 31 2024	n/a	n/a	-€8m
Dec 31 2023	€301k	€180k	-€7m
Sep 30 2023	n/a	n/a	-€8m
Jun 30 2023	n/a	n/a	-€9m
Mar 31 2023	n/a	n/a	-€11m
Dec 31 2022	€318k	€180k	-€12m
Sep 30 2022	n/a	n/a	-€11m
Jun 30 2022	n/a	n/a	-€10m
Mar 31 2022	n/a	n/a	-€9m
Dec 31 2021	€259k	€180k	-€9m

Compensatie versus markt: De totale vergoeding ($USD 315.35K ) Sebastien } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 472.15K ).

Compensatie versus inkomsten: De vergoeding van Sebastien is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Sebastien Peltier (46 yo)

7.7yrs

Tenure

€301,000

Compensatie

Mr. Sebastien Peltier, Ph D., HDR serves as the Chief Executive Officer of Valbiotis SA and is Co-Founder of Valbiotis. Mr. Peltier has been Member of Management Board of Valbiotis SA from March 7, 2017 an...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Sebastien Peltier	Co-Founder	7.7yrs	€301.00k	4% € 769.7k
Sebastien Bessy	COO & Member of the Management Board	3.4yrs	€295.00k	0.035% € 6.7k
Pascal Sirvent	CSO & Member of the Management Board	6.2yrs	€236.00k	0.12% € 23.4k
Murielle Cazaubiel	CMO & Member of the Management Board	5.8yrs	€255.00k	0.0026% € 500.0
Stanislas Sordet	CFO & Member of Management Board	less than a year	geen gegevens	geen gegevens
Charlotte Jezequel	Director of HR & Member of Management Board	1.8yrs	geen gegevens	geen gegevens
Josep Infesta	Head of Global Business Development	5.8yrs	geen gegevens	geen gegevens

5.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van 8JD is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Agnes Tixier	Member of Supervisory Board	5.7yrs	geen gegevens	geen gegevens
Laurent Levy	Chairman of Supervisory Board	7.7yrs	geen gegevens	geen gegevens
Nathalie Boisseau	Member of Scientific & Medical Board	no data	geen gegevens	geen gegevens
Jean-Marie Bard	Member of Scientific & Medical Board	no data	geen gegevens	geen gegevens
Samy Hadjadj	Member of Scientific & Medical Board	no data	geen gegevens	geen gegevens
Thierry Maugard	Member of Scientific & Medical Board	no data	geen gegevens	geen gegevens
Bruno Guigas	Member of Scientific & Medical Board	no data	geen gegevens	geen gegevens
André Marette	Member of Scientific & Medical Board	no data	geen gegevens	geen gegevens
Jean Zetlaoui	Member of Supervisory Board	7.1yrs	geen gegevens	geen gegevens

7.1yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van 8JD wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.1 jaar).

Valbiotis Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Valbiotis SA, Annual General Meeting, Jun 25, 2024

Valbiotis Appoints Frédéric PELONG to Board of Directors

Valbiotis Appoints Frédéric PELONG to Board of Directors

No independent directors

Valbiotis Announces Board of Directors Changes

Recent updates

New minor risk - Profitability

New major risk - Share price stability

Valbiotis SA, Annual General Meeting, Jun 25, 2024

Full year 2023 earnings released

New minor risk - Shareholder dilution

New minor risk - Profitability

Valbiotis SA has filed a Follow-on Equity Offering in the amount of €15.000001 million.

Valbiotis SA Presents the Full Results of the Phase II/III REVERSE-IT Study: Impressive Efficacy of TOTUM 63 Against Prediabetes and the Early Stages of Type 2 Diabetes, a First for a Non-drug Active Substance

Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM-63

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released

Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM--854 Clinical Study, Against High Blood Pressure

Forecast breakeven date pushed back to 2024

Valbiotis SA announced that it has received €9.7 million in funding

Valbiotis SA Presents Additional Positive Results from the HEART Clinical Study on TOTUM•070 for Hypercholesterolemia

First half 2022 earnings released

Valbiotis Appoints Frédéric PELONG to Board of Directors

Valbiotis Appoints Frédéric PELONG to Board of Directors

Valbiotis Announces Completion of Recruitment for the Phase Ii/Iii Reverse-It Clinical Study with Totum•63 Against Prediabetes, in Partnership with Nestlé Health Science

Valbiotis Announces the Major Success of the Phase II Heart Clinical Study the Patented Plant-Based Active Substance Totum•070 Proves Its Efficacy Against Hypercholesterolemia, A Cardiovascular Risk Factor

No independent directors

Valbiotis SA Announces the Positive Results of Its Clinical Study on the Bioavailability and Mode of Action of TOTUM•070, Against Hypercholesterolemia

Full year 2021 earnings: Revenues miss analyst expectations

Valbiotis Announces Board of Directors Changes

Valbiotis SA to Report Fiscal Year 2021 Results on Mar 15, 2022

Valbiotis Announces Approval to Launch the Two Phase II/III Insight and Insight 2 Clinical Studies, the Last Step in the Development of Totum•854 for the Reduction of Blood Pressure

Forecast to breakeven in 2023

Valbiotis Submits to the Competent Authorities the Three Clinical Protocols for TOTUM•854 Indicated in the Reduction of Blood Pressure and Presents its Comprehensive Clinical Development Plan

First half 2021 earnings released

Valbiotis Announces the Publication of the First Scientific Papers on TOTUM•63 in Three International Journals, Elucidating Its Multitarget Mode of Action

Full year 2020 earnings released

Valbiotis SA to Report First Half, 2021 Results on Sep 30, 2021

Valbiotis Selected to Present TOTUM-854 Results on Arterial Hypertension

Valbiotis SA Announces the First Patient’s First Visit in the Phase II HEART Clinical Study on TOTUM-070 and Steps up Its Research Program Against Hypercholesterolemia in 2021

Valbiotis Authorizes to Launch Heart, the Phase II Multi-Center Clinical Study with TOTUM-070, for the Reduction of Blood LDL-Cholesterol Levels

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur